Home    About Us    Contact US     

Welcome to Sterling Biotech Limited 

Welcome to Sterling Biotech Limited!

Working with and developing any opportunity into reality is a mindset at Sterling Group. Sterling with its new thinking, new capabilities and sense of urgency aspires to "Earn trust, every moment" of its partners, collaborators, stake holders and customers. At Sterling Biotech Ltd. our goal is to commercialize new product in areas of neutraceutical, biopharmaceutical, pharmaceutical and make it available at competitive prices to our customers.

Our capabilities include state of art research centre, advance pilot plants for scale up studies, modern facility of bioreactors and range of down streaming process equipments. All this is coupled with dedicated and qualified work force, well equipped quality control laboratory and quality assurance systems.

In a short span of two years, Sterling Biotech Ltd. has launched Co-enzyme Q10, started a new modern research facility approved by DST / CSIR and an advance intermediate contract manufacturing site for a multi-national company.

We strive to become leaders in neutraceutical and biopharmaceutical area by developing state of the art facility for research and development, contract manufacturing of active pharmaceutical ingredients and formulation products. We build quality in every aspect of manufacturing with particular laid down emphasis based on current Good Manufacturing Practices.

Sterling Biotech Ltd. is committed to scaling new heights and creating new dimensions in biopharmaceutical and neutraceutical range of products. This way we shall support aspiration to "Live better and Live longer".

Sterling Biotech's manufacturing facility at Masar, Gujarat, is at par with international standards. It complies with cGMP norms complying to the standards of WHO and is in the process of getting COS for the active pharmaceutical ingredient, Ubidecarenone (Coenzyme Q10).

This adequately reflects Sterling’s commitment towards quality. Efforts to attain such standards have also opened the key to gain foothold in the regulated and semi regulated markets throughout US and Europe